Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink

[1] Collaborators CTT'(CTT)(2013)Heart Disease and Stroke Statistics—2013 Update Circulation 127 e6-e245

[2] Sattar N(2012)The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Eur Heart J 33 1635-1701

[3] Preiss D(2005)Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267-1278

[4] Murray HM(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 1670-1681

[5] Welsh P(2012)The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 581-590

[6] Buckley BM(2012)Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy PLoS One 7 e29849-742

[7] de Craen AJ(2010)Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 735-124

[8] Seshasai SR(2011)Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials QJM 104 109-362

[9] McMurray JJ(2001)Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 357-2207

[10] Freeman DJ(2008)Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195-1929

[1] Collaborators CTT'(CTT)(2013)Heart Disease and Stroke Statistics—2013 Update Circulation 127 e6-e245

[2] Sattar N(2012)The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Eur Heart J 33 1635-1701

[3] Preiss D(2005)Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267-1278

[4] Murray HM(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 1670-1681

[5] Welsh P(2012)The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 581-590

[6] Buckley BM(2012)Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy PLoS One 7 e29849-742

[7] de Craen AJ(2010)Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 735-124

[8] Seshasai SR(2011)Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials QJM 104 109-362

[9] McMurray JJ(2001)Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 357-2207

[10] Freeman DJ(2008)Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195-1929